科室与专家门诊

妙佑医疗国际是美国规模最大、经验最丰富的医疗机构之一,在亚利桑那州、佛罗里达州和明尼苏达州都有院区。医务人员掌握数几十种专业技能,齐心协力,确保高品质治疗与成功康复。

治疗此病症的医生

编辑搜索过滤条件
close

缩小搜索范围

重置所有过滤器

显示$起始范围 - $结束范围/源自可用$可用医生

姓氏首字母: C

  1. Ruqin Chen, M.D., M.B.

    Ruqin Chen, M.D., M.B.

    1. Oncologist
    1. Jacksonville, FL
    擅长领域:

    Chemotherapy, Immunotherapy, Targeted drug therapy, Hormone therapy for prostate cancer, Kidney cancer, Prostate cancer..., Bladder cancer, Melanoma

  2. Scott M. Cheney, M.D.

    Scott M. Cheney, M.D.

    1. Phoenix, AZ
    擅长领域:

    Robotic surgery, Nephrectomy, Prostatectomy, Partial nephrectomy, HoLEP, Ureteroscopy, Laparoscopic surgery, Kidney can...cer, Kidney stone, Prostate cancer, Bladder cancer, Ureteropelvic junction obstruction, Prostate disorder

  3. Dan S. Childs, M.D.

    Dan S. Childs, M.D.

    1. Oncologist
    1. Rochester, MN
    擅长领域:

    Cancer survivorship program, Cancer treatment, Cancer, Kidney cancer, Prostate cancer, Bladder cancer, Testicular cance...r, Rare disorders

  4. C. Richard Choo, M.D.

    C. Richard Choo, M.D.

    1. Radiation Oncologist
    1. Rochester, MN
    擅长领域:

    Brachytherapy, Proton therapy, Radiation therapy, Intensity-modulated radiation therapy, Prostate cancer, Bladder cance...r, Testicular cancer

研究

外科医生在和前列腺癌患者交谈 妙佑医疗国际的外科医生在解释前列腺癌的所有治疗方案

妙佑医疗国际的医生和科学家是前列腺癌研究领域的佼佼者。重点领域包括创新诊断技术、探索和完善治疗选项、了解提高生活质量的方法和分析长期随访数据。

几十年来,妙佑医疗国际一直在维护男性前列腺癌手术患者的数据库。研究人员利用这些信息来监测结果,寻找趋势,确定有效的治疗方法和确保整体护理质量。

妙佑医疗国际综合癌症中心合作开展前列腺癌研究。妙佑医疗国际综合癌症中心获得美国国家癌症研究所的资助,并被指定为综合癌症中心,这是对其在癌症预防、诊断和治疗方面的卓越科学成就和多学科资源的认可。

文献

请参阅美国国家医学图书馆检索服务系统 PubMed 所收录的妙佑医疗国际的医生在前列腺癌领域发表的文献目录

Research Profiles

查看所有医生 • 所有位置

June 14, 2024

Living with 前列腺癌?

Connect with others like you for support and answers to your questions in the Prostate Cancer support group on Mayo Clinic Connect, a patient community.

Prostate Cancer Discussions

bl2023
Final decision on treatment: Viewray or Truebeam?

36 Replies Sun, Nov 17, 2024

dodgerblue
Intraductal prostate carcinoma: What is standard treatment?

26 Replies Sun, Nov 17, 2024

See more discussions